目的 研究益心酮片联合盐酸曲美他嗪片治疗冠心病心绞痛的临床疗效。方法 选取2018年10月-2019年10月天津市第三中心医院分院收治的100例冠心病心绞痛患者为研究对象，将所有患者随机分为对照组和治疗组，每组各50例。对照组患者口服盐酸曲美他嗪片，1片/次，3次/d。治疗组在对照组基础上口服益心酮片，3片/次，3次/d。两组患者持续治疗30 d。观察两组患者临床疗效，比较两组临床症状情况、西雅图心绞痛量表评分、心功能指标、血管内皮功能因子、炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为82.00%、96.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数、心绞痛持续时间明显降低，西雅图心绞痛量表评分明显升高（P<0.05）；且治疗组改善较多（P<0.05）。治疗后，两组患者每搏射血量（SV）、心脏指数（CI）和左室射血分数（LVEF）显著升高（P<0.05）；且治疗组SV、CI和LVEF比对照组升高较多（P<0.05）。治疗后，两组血清内皮素-1（ET-1）水平显著降低，血清二氧化氮（NO）水平明显升高（P<0.05）；且治疗组改善较多（P<0.05）。治疗后，两组患者血清基质金属蛋白酶-9（MMP-9）、超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）水平显著降低（P<0.05）；且治疗组血清MMP-9、hs-CRP和IL-6水平较对照组降低较多（P<0.05）。结论 益心酮片联合盐酸曲美他嗪片治疗冠心病心绞痛具有较好的治疗效果，能改善患者临床症状和心功能，调节血清血管内皮功能因子和炎性因子水平，值得在临床上推广应用。

Qbjective To study the effect of Yixintong Tablets combined with Trimetazidine Hydrochloride Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (100 cases) with angina pectoris of coronary heart disease in the Branch of Tianjin Third Central Hospital from October 2018 to October 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Yixintong Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacies were evaluated, and clinical symptoms, Seattle angina scale score, cardiac function index, vascular endothelial function factor, inflammatory factor level in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 96.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly reduced, but Seattle angina scale score was significantly increased (P<0.05), and these indexes in the treatment group were improved more than those in the control group (P<0.05). After treatment, the SV, CI, and LVEF in two groups were significantly increased (P<0.05), and the SV, CI, and LVEF in the treatment group were increased more than those in the control group (P<0.05). After treatment, the serum levels of ET-1 in two groups were significantly decreased, but the serum levels of NO were significantly increased (P<0.05), and these indexes in the treatment group were improved more than those in the control group (P<0.05). After treatment, the levels of MMP-9, hs-CRP, and IL-6 in two groups were significantly reduced (P<0.05). And the levels of MMP-9, hs-CRP, and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Yixintong Tablets combined with Trimetazidine Hydrochloride Tablets has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve the clinical symptoms and heart function of patients, regulate the serum level of vascular endothelial function factor and inflammatory factor, which is worthy of clinical application.

R972